Dongsung Pharmaceutical

동성제약 · 002210

Health Care Pharmaceuticals · KOSPI

Small-cap

Market cap US$68.1M (₩94B)

Overview

Dongsung Pharmaceutical makes medicines and health-care products supplied to patients and the broader Korean health-care market.

The company is listed on KOSPI, South Korea's main stock exchange. The filing's table of contents covers pharmaceuticals as its core business, alongside research and development activities, but does not detail a single dominant product line beyond the general pharmaceutical scope.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$63.2M

▼ −1.4% YoY

Operating profit · FY2025

−US$7.3M

Loss widened

Net income · FY2025

−US$18.7M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$64.2M(₩88.6B)	US$64.1M(₩88.4B)	US$63.2M(₩87.2B)
Operating profit	US$432.2K(₩596.4M)	−US$4.2M(−₩5.7B)	−US$7.3M(−₩10.1B)
Net income	−US$1.5M(−₩2.1B)	−US$10.6M(−₩14.6B)	−US$18.7M(−₩25.7B)

Revenue

FY2023US$64.2M
FY2024US$64.1M
FY2025US$63.2M

Operating profit

FY2023US$432.2K
FY2024−US$4.2M
FY2025−US$7.3M

Net income

FY2023−US$1.5M
FY2024−US$10.6M
FY2025−US$18.7M

Key ratios (FY2025)

ROE

-110.1%

Debt/Eq

620.7%

Op. margin

-11.6%

Net margin

-29.5%

Rev. YoY

▼ −1.4%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?